Is CTXR undervalued or overvalued?
As of 2025-03-26, the Intrinsic Value of Citius Pharmaceuticals Inc (CTXR) is -23.09 USD. This CTXR valuation is based on the model Peter Lynch Fair Value. With the current market price of 1.47 USD, the upside of Citius Pharmaceuticals Inc is -1,671.04%. This means that CTXR is overvalued by 1,671.04%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -23.09 - -23.09 | -23.09 | -1,671.04% |
| DDM - Stable | (31.00) - (141.60) | (86.30) | -5970.9% |
| DDM - Multi | (24.90) - (95.15) | (40.25) | -2838.2% |
| Market Cap (mil) | 12.63 |
| Beta | 1.22 |
| Outstanding shares (mil) | 8.59 |
| Enterprise Value (mil) | 12.63 |
| Market risk premium | 4.60% |
| Cost of Equity | 10.68% |
| Cost of Debt | 5.00% |
| WACC | 7.81% |